Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
机构：[1]Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People’s Republic of China四川省肿瘤医院[2]Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China四川大学华西医院[3]Department of Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People’s Republic of China四川省肿瘤医院
Purpose: We compare the efficacy and safety of regorafenib plus immune checkpoint inhibitors (ICIs) with transarterial chemoem-bolization (R+ICIs+TACE) versus regorafenib plus ICIs (R+ICIs) as the second-line treatment for patients with advanced hepatocel-lular carcinoma (HCC).Methods: This retrospective study included patients with advanced HCC who received R+ICIs+TACE or R+ICIs as the second-line treatment from January 2019 to April 2022. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) were compared between the two groups. The propensity score matching (PSM) was used to reduce the influence of confounding factors on the outcomes. Factors affecting PFS and OS were analyzed using a Cox proportional-hazards regression model.Results: In total, 52 patients were included in this study, of whom 28 patients received R+ICIs+TACE and 24 patients received R+ICIs. After PSM (n=23 in each group), patients who received R+ICIs+TACE had a higher ORR (34.8% vs 4.3%, P=0.009), a longer PFS (5.8 vs 2.6 months, P<0.0001), and a longer OS (15.0 vs 7.5 months, P=0.014) than those who received R+ICIs. Age <= 50 years old, Child -Pugh class A6 and B7, and R+ICIs were found as independent prognostic factors for poor PFS. R+ICIs, alpha-fetoprotein >400 ng/mL, and platelet-to-lymphocyte ratio >133 were noted as independent prognostic factors for poor OS. The difference in the incidence of TRAEs between the two groups was not statistically significant (P> 0.05).Conclusion: Compared to regorafenib plus ICIs, regorafenib plus ICIs with TACE was tolerated and improved survival as the second -line treatment for patients with advanced HCC.
基金：
Natural Science Foundation of Sichuan Province [2022NSFSC0837]; Science and Technology Program of Chengdu, China [2022-YF05-01811-SN]; Wu Jieping Medical Foundation [320.6750.2020-10-122]; Beijing Medical Award Foundation [YXJL-2020-0972-0424]; Beijing Xisike Clinical Oncology Research Foundation [Y-HR2020MS-0484]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21041]; National Key R&D Program of China [2022YFC2404105]
第一作者机构：[1]Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People’s Republic of China[2]Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
通讯作者：
通讯机构：[1]Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, People’s Republic of China[2]Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China[*1]Department of Interventional Therapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, 55 Renmin South Road 4th Section, Chengdu, Sichuan, 610041, People’s Republic of China[*2]Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, People’s Republic of China
推荐引用方式(GB/T 7714)：
Yang Xuegang,Deng Heping,Sun Yanyuan,et al.Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis[J].JOURNAL OF HEPATOCELLULAR CARCINOMA.2023,10:303-313.doi:10.2147/JHC.S399135.
APA：
Yang, Xuegang,Deng, Heping,Sun, Yanyuan,Zhang, Yi,Lu, Yujie...&Huang, Xiaoqi.(2023).Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.JOURNAL OF HEPATOCELLULAR CARCINOMA,10,
MLA：
Yang, Xuegang,et al."Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis".JOURNAL OF HEPATOCELLULAR CARCINOMA 10.(2023):303-313
